Castle Biosciences (CSTL) Enterprise Value (2018 - 2026)

Castle Biosciences has reported Enterprise Value for 9 years, with the latest figure at -$266.8 million in Q2 2026.

• Quarterly Enterprise Value rose 3.3% year-over-year to -$266.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$266.8 million (up 3.3% YoY) and the FY2025 annual result came in at -$299.5 million, down 2.17% from the prior year.
• Enterprise Value declined to -$266.8 million in Q2 2026 per CSTL's latest filing, from -$261.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$225.5 million in Q2 2023 and troughed at -$309.0 million in Q1 2022.
• A 5-year average of -$265.3 million and a median of -$266.4 million in 2022 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value advanced 26.76% in 2022, then declined 21.79% in 2024.
• Over 5 years, Enterprise Value stood at -$258.6 million in 2022, then climbed by 6.0% to -$243.1 million in 2023, then dropped by 20.58% to -$293.1 million in 2024, then slipped by 2.17% to -$299.5 million in 2025, then climbed by 10.91% to -$266.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$266.8 million, -$261.7 million, and -$299.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.